NEWS WE WERE WAITING FOR
We were indeed waiting for news to come from Amgen about the fate of the heart failure drug Omecamtiv mecarbil. The reason is that heart failure treatments are not really working as expected and some studies began to suggest that abandoning the old inexpensive drug digoxin in favor of non-specific cardiac muscle drugs was in the least not well advised.
So, in the news, Amgen (AMGN) and Cytokinetics (CYTK) finally announced that they are expanding their strategic collaboration to include Japan. Of course the collaboration is about discovering and developing small molecule therapeutics that activate the heart (cardiac) muscle contractility for potential applications in the treatment of heart failure. The original agreement was signed way back in 2006 when Cytokinetics` licensed to Amgen omecamtiv mecarbil molecules for heart failure excluded Japan.
Since that time, investors have been waiting to see whether Amgen believes in the value of Cytokinetics' drug. We got hint about good news once or twice and we were comforted only knowing that Amgen did not cancel the agreement with Cytokinetics whose stock kept losing value caused by the lack of news from Amgen.
Under the amendment to the announced collaboration, the companies have agreed on expanding Amgen`s license for omecamtiv mecarbil and related compounds to include Japan. So, Amgen believes in the drug's merit, which is good news that we needed to hear. Good news also for Cytokinetics is that it will receive $25 million from Amgen comprised of a non-refundable license fee of $15 million and $10 million for Amgen`s purchase of Cytokinetics` common stock.
Comforting news also is that announcing that Amgen will be investing in iCYTK. Knowing in fact that Amgen is the last to throw money made us gain more comfort and confidence about Cytokinetics' research in general and omecamtiv mecarbil in special.
The companies have executed a stock purchase agreement providing for the sale of Cytokinetics` common stock to Amgen at a price per share equal to the 10-day trailing average of the closing price of Cytokinetics` stock on the last trading day prior to execution of the stock purchase agreement. In addition,
Cytokinetics is also eligible to receive additional pre-commercialization milestone payments for the development of omecamtiv mecarbil in Japan of up to $50 million as well as royalties on sales of omecamtiv mecarbil in Japan.
Under the terms of the amended collaboration agreement, Cytokinetics plans to conduct a Phase I pharmacokinetic study in Japan, the costs of which will be reimbursed by Amgen. Amgen is intended to support the inclusion of Japanese patients in a potential Phase 3 clinical development program for omecamtiv mecarbil.
Robert I. Blum, Cytokinetics` President and Chief Executive Officer stated that his firm's decision to amend the agreement at this time is based on its confidence in the progress of the collaborative development program for omecamtiv mecarbil and on Amgen`s recent commitment to expand its business activities in Japan.
Sean E. Harper, M.D., Amgen`s Executive Vice President of Research and Development said, "This expanded collaboration furthers Amgen`s hopes to address needs of patients with heart failure in Japan."
Omecamtiv mecarbil is a small molecule cardiac myosin activator, which was discovered by Cytokinetics` scientists. It is being investigated for the treatment of heart failure.
All we can say is good luck. The fact is that we are in bad need for cardiac muscle failure drug that exerts its action on the heart muscle. Omecamtiv mecarbil does.
We long both firms mentioned in this article
FORWARD-LOOKING: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our 'opinions' and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.